Navigation Links
BioLife Solutions Products Now Used in More than 50 Clinical Trial-Stage Cellular Therapies
Date:10/29/2012

BOTHELL, Wash., Oct. 29, 2012 /PRNewswire/ -- BioLife Solutions, Inc. (OTCBB: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media for cells and tissues, and contract aseptic media manufacturer, today announced the Company's novel biopreservation technology is being used in more than 50 clinical trial-stage cellular therapies, making it the leading choice in the emerging, high growth field of regenerative medicine. Management believes that the Company holds the number one supplier position among companies offering pre-formulated cell and tissue storage and freeze media used in clinical trial stage cellular therapies to treat the leading causes of death and disability such as cancer, heart disease, stroke, and joint/movement disorders.

(Photo:  http://photos.prnewswire.com/prnh/20121029/LA01346-INFO)

(Logo:  http://photos.prnewswire.com/prnh/20090814/BIOLIFELOGO)

BioLife Chief Executive Officer Mike Rice indicated that the Company's revenue from its growing regenerative medicine customer base, along with its selective targeting of contract manufacturing customers, should generate cash and profits in the interim until some regenerative medicine customers gain approval and adoption. At that point, profitable growth should accelerate in a step-wise fashion.

Rice commented: "We've built a very strong franchise for HypoThermosol® and CryoStor® in developing commercial cell and tissue-based products and therapies.  It's very satisfying to see the biopreservation efficacy and best-in-class quality of our products recognized by more companies and hospital-based transplant centers using pre-formulated storage, shipping, and freeze media products. Since 2006, we've consistently converted these customers from using 'home-brew' formulations to our cGMP, protein-free, serum-free biopreservation media products."

Based on customers cross-referencing BioLife's FDA Master Files for its HypoThermosol and CryoStor products for use in their regulatory filings, customer orders, and other customer communication, BioLife management believes the Company's potential annual revenue from the regenerative medicine market could reach $50 million over the next several years, should its customers be successful in obtaining regulatory approval for their cell-based products currently in clinical trials.

A recent visiongain report "Translational Regenerative Medicine: Market Prospects 2012-2022" values the regenerative medicine market at $1.4 billion in 2012, and growing to $10 billion by 2020.  BioLife's addressable portion of the market is the demand for reagents used to store, ship and freeze source material and manufactured doses of cell-based products and therapies.

Rice continued, "The challenges in commercializing cell-based products have been exposed since the first few approvals were granted.  Product shelf life and post-preservation viability are critical to good clinical outcomes and commercial success, and we're pleased to see the field recognize the reduction in overall manufacturing costs that can be enabled through the use of our products.  Bioprocessing and biopreservation are executed along a continuum, with cumulative positive and negative yield and cost impact, depending on the quality and performance of the tools and reagents used along the way.  HypoThermosol and CryoStor are recognized as critical reagents and we're looking forward to seeing our customers' products in the market and available to clinicians and patients in the years to come."

BioLife Solutions is co-sponsoring the Stem Cells on the Mesa conference October 29 – 30, in La Jolla, CA.  The Company plans to file its 10-Q quarterly report for the third quarter of 2012 on November 13.

About BioLife SolutionsBioLife Solutions develops, manufactures and markets patented hypothermic storage and cryopreservation solutions for cells and tissues.  The Company's proprietary HypoThermosol® and CryoStor® platform of solutions are marketed to academic and commercial organizations involved in cell therapy, tissue engineering, cord blood banking, drug discovery, and toxicology testing. BioLife's products are serum-free and protein-free, fully defined, and are formulated to reduce preservation-induced, delayed-onset cell damage and death.  BioLife's enabling technology provides academic and clinical researchers significant improvements in post-thaw cell, tissue, and organ viability and function.  For more information please visit www.biolifesolutions.com, and follow BioLife on Twitter.

This news release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995.  These forward-looking statements include any statements that relate to the intent, belief, plans or expectations of the Company or its management, or that are not a statement of historical fact.  Any forward-looking statements in this news release are based on current expectations and beliefs and are subject to numerous risks and uncertainties that could cause actual results to differ materially. Some of the specific factors that could cause BioLife Solutions' actual results to differ materially are discussed in the Company's recent filings with the Securities and Exchange Commission.  BioLife Solutions disclaims any obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.  Media Relations:

Investor Relations:Len Hall

Matt ClawsonAllen & Caron Inc

Allen & Caron Inc(949) 474-4300

(949) 474-4300len@allencaron.com

matt@allencaron.com


'/>"/>
SOURCE BioLife Solutions, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology news :

1. BioLife Solutions Announces 7th Consecutive Quarter of Record Revenue
2. Advanced Clinical Joins MedNet Solutions iMedNet Partner Program
3. Statistics & Data Corporation Selects MedNet Solutions As Strategic Technology Partner
4. CEVA, Rubidium Partner to Deliver Speech Processing Solutions based on the CEVA-TeakLite Family of DSPs
5. Novetta Solutions Acquires International Biometric Group, LLC
6. MedNet Solutions Announces Latest Enhancements To Its iMedNet EDC eClinical Solution
7. uAttend Time Tracking Solutions Available at TimeClockDeals.com
8. Validity CTO to Present Natural ID Solutions for Improving Mobile Risk Management and User Experience at NFC Solutions Summit 2012
9. CDS Monarch Deploys DigitalPersona Strong Authentication Solutions for Secure Access to Electronic Medical Records
10. University of Minnesota startup offers game-changing energy solutions that reduce CO2 emissions
11. MedNet Solutions to Demonstrate Its Innovative Suite of eClinical Solutions at the 2012 Bio-IT World Conference & Expo
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/9/2016)... 2016 Paris Police Prefecture ... security solution to ensure the safety of people and operations ... the major tournament Teleste, an international technology group ... announced today that its video security solution will be utilised ... up public safety across the country. The system roll-out is ...
(Date:6/3/2016)... 2016 Das DOTM ... Nepal hat ein 44 Millionen ... Kennzeichen, einschließlich Personalisierung, Registrierung und IT-Infrastruktur, an ... und Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte internationale ... teilgenommen, aber Decatur wurde als konformste und ...
(Date:6/2/2016)... --  The Weather Company , an IBM Business (NYSE: ... in which consumers will be able to interact with IBM ... voice or text and receive relevant information about the product ... have long sought an advertising solution that can create a ... and valuable; and can scale across millions of interactions and ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... ... , ... Supplyframe, the Industry Network for electronics hardware design ... Located in Pasadena, Calif., the Design Lab’s mission is to bring together inventors ... and brought to market. , The Design Lab is Supplyframe’s physical representation of ...
(Date:6/23/2016)... 23, 2016 Apellis Pharmaceuticals, Inc. today ... trials of its complement C3 inhibitor, APL-2. The ... ascending dose studies designed to assess the safety, ... injection in healthy adult volunteers. Forty ... a single dose (ranging from 45 to 1,440mg) ...
(Date:6/23/2016)... On Wednesday, June 22, 2016, the ... the Dow Jones Industrial Average edged 0.27% lower to finish ... 0.17%. Stock-Callers.com has initiated coverage on the following equities: Infinity ... NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ... ). Learn more about these stocks by accessing their free ...
(Date:6/23/2016)... ... 2016 , ... Velocity Products, a division of Morris Group, ... exclusively for Okuma CNC machining centers at The International Manufacturing Technology Show, IMTS, ... companies with expertise in toolholding, cutting tools, machining dynamics and distribution, Velocity SMART ...
Breaking Biology Technology: